DigiTx Partners

DigiTx Partners, established in 2016 and based in San Francisco, is a venture capital firm focused on investing in digital health and healthcare technology systems. The company supports innovative startups that aim to transform the healthcare ecosystem by improving patient navigation, integrating diagnostic and treatment processes, accelerating drug development, and enhancing physician-patient interactions. DigiTx Partners backs companies that strive to advance healthcare and keep people healthier.

Anish Aitharaju

Investor

Isabelle Chae

Investor

David Kim

Managing Director

Miraj Sanghvi

Partner

Keisuke Mitsuoka Ph.D

Venture Partner

Sumiho Nakatsu Ph.D

Venture Partner

26 past transactions

Cerula Care

Seed Round in 2025
Cerula Care is a behavioral health company that focuses on providing services for individuals with advanced chronic conditions. The company offers virtual care solutions, including care management, coaching, and psychiatric support, aimed at addressing mental health issues such as anxiety, depression, substance use disorder, and post-traumatic stress disorder. By leveraging these services, Cerula Care seeks to enhance behavioral health outcomes for its patients, ensuring they receive comprehensive support tailored to their specific needs.

StrokeDx

Seed Round in 2024
StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

CardioSignal

Series A in 2024
CardioSignal is a medical technology company focused on the detection of heart diseases, particularly atrial fibrillation. Originally an academic spinoff, it has developed a patented mobile application that serves as a certified medical device for self-monitoring, remote care, and point-of-care diagnostics. The application utilizes advanced algorithms to provide users with features such as atrial fibrillation detection, vital signs monitoring, measurement history, and personalized insights. By enabling users to track their heart health, CardioSignal aims to facilitate early detection and prevention of serious cardiovascular events such as strokes and heart attacks, ultimately improving patient outcomes.

Rune Labs

Venture Round in 2024
Rune Labs, Inc. is a technology company that offers a software-as-a-service platform designed to support neuromodulation systems in managing complex therapies. Established in 2018 and headquartered in San Francisco, California, the platform integrates brain imaging and electrophysiology data from clinical studies and patient care, making it valuable for neuroscience therapeutics. Rune Labs primarily serves pharmaceutical and med-tech companies, assisting them in developing precision therapies for conditions such as Parkinson's disease, epilepsy, depression, and obsessive-compulsive disorder. The platform provides a secure, cloud-based infrastructure that enables clients to efficiently analyze large volumes of brain data, facilitating the implementation of sophisticated therapy algorithms and enhancing the precision of medicine delivered to patients.

Ciba Health

Series A in 2023
Ciba Health is a personalized digital therapeutics and virtual care platform that focuses on treating and reversing chronic conditions through a precision health approach. The company empowers patients by promoting self-care and offering a patient-centered, root-cause methodology. Ciba Health emphasizes a value-based care delivery model that integrates full-spectrum care, providing convenient access to multidisciplinary teams. By leveraging advanced technology, it implements individualized treatment plans that address the physical, mental, and lifestyle needs of patients, fostering improvements in overall well-being.

Tali AI

Seed Round in 2023
Tali AI is a technology company specializing in voice-enabled virtual assistants for healthcare professionals. Their primary product is an assistant that integrates with electronic health records (EHR), allowing physicians to dictate patient notes directly into the system. This platform aims to streamline workflows, reduce manual data entry, and improve overall efficiency within medical practices.

FIGUR8

Series A in 2023
FIGUR8, Inc. is a Boston-based company founded in 2016 as an MIT spin-off, specializing in advanced wearable sensor technology to measure body movement related to musculoskeletal (MSK) conditions. The company's innovative solution integrates smart biosensors, intuitive software, and artificial intelligence to collect and analyze movement data without the need for cumbersome cameras. This technology accurately identifies the sources of MSK pathology, providing essential insights that enhance patient recovery and care management. By enabling trainers, therapists, and physicians to objectively assess musculoskeletal performance, FIGUR8's platform not only improves access to care but also empowers patients to take control of their health. The comprehensive approach records value throughout the entire episode of care, from injury to recovery, ultimately reducing costs and improving health outcomes.

Mightier

Series B in 2021
Mightier is a Boston-based gaming platform established in 2016 that focuses on helping children develop emotional regulation skills through bioresponsive video games. The company's innovative program, developed in collaboration with Boston Children's Hospital and Harvard Medical School, utilizes a heart rate monitor to create a unique gaming experience where the game's difficulty adjusts based on the player's emotional state. This approach allows children to visualize their emotions in real-time, enabling them to learn how to manage their feelings effectively. By engaging with these games, kids with behavioral and emotional challenges can discover their emotional strengths and improve their ability to cope with daily situations.

Rune Labs

Series A in 2021
Rune Labs, Inc. is a technology company that offers a software-as-a-service platform designed to support neuromodulation systems in managing complex therapies. Established in 2018 and headquartered in San Francisco, California, the platform integrates brain imaging and electrophysiology data from clinical studies and patient care, making it valuable for neuroscience therapeutics. Rune Labs primarily serves pharmaceutical and med-tech companies, assisting them in developing precision therapies for conditions such as Parkinson's disease, epilepsy, depression, and obsessive-compulsive disorder. The platform provides a secure, cloud-based infrastructure that enables clients to efficiently analyze large volumes of brain data, facilitating the implementation of sophisticated therapy algorithms and enhancing the precision of medicine delivered to patients.

Cleerly

Series B in 2021
Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

Nesos

Venture Round in 2020
Nēsos specializes in the development and commercialization of electrical field treatments aimed at addressing neurological disorders. The company focuses on creating therapeutic earbuds that facilitate drug-free, non-invasive treatments by utilizing existing nerve pathways to stimulate target brain regions. This innovative approach enables medical practitioners to treat conditions such as rheumatoid arthritis by harnessing the principles of neuroplasticity. Nēsos benefits from the collaboration of prominent clinical and scientific experts from esteemed academic institutions, including Stanford, Harvard, and Mount Sinai, among others. Co-founded by Konstantinos Alataris and a team of neuroscientists, Nēsos is committed to advancing therapies that improve immune function and overall neurological health.

Eko Health

Series C in 2020
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Rune Labs

Seed Round in 2020
Rune Labs, Inc. is a technology company that offers a software-as-a-service platform designed to support neuromodulation systems in managing complex therapies. Established in 2018 and headquartered in San Francisco, California, the platform integrates brain imaging and electrophysiology data from clinical studies and patient care, making it valuable for neuroscience therapeutics. Rune Labs primarily serves pharmaceutical and med-tech companies, assisting them in developing precision therapies for conditions such as Parkinson's disease, epilepsy, depression, and obsessive-compulsive disorder. The platform provides a secure, cloud-based infrastructure that enables clients to efficiently analyze large volumes of brain data, facilitating the implementation of sophisticated therapy algorithms and enhancing the precision of medicine delivered to patients.

G-Tech Medical

Series A in 2020
G-Tech Medical is focused on developing a wireless, wearable, and disposable electrode patch known as the GutCheck patch, which measures the electrical activity of the gastrointestinal tract, specifically the stomach, small intestine, and colon. This innovative diagnostic device addresses the challenges of diagnosing functional disorders in patients experiencing abdominal pain, constipation, diarrhea, or bloating, conditions that often go undetected through traditional methods like colonoscopies or CT scans. By monitoring myoelectrical signals over several days, G-Tech's system provides a non-invasive solution that enables physicians to assess gastrointestinal motility more effectively, ultimately aiming to enhance patient outcomes and reduce healthcare costs associated with gastrointestinal conditions.

nQ Medical

Seed Round in 2019
nQ Medical Inc., founded in 2016 and based in Cambridge, Massachusetts, is a digital therapeutics company focused on transforming the management of neurocognitive and neuromotor disorders. The company has developed an artificial intelligence tool called neuroQWERTY that facilitates early detection and remote monitoring of diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. By passively collecting data from users' interactions with everyday electronic devices, nQ Medical captures subtle changes in motor function and cognitive abilities that may indicate disease progression. This innovative approach allows for continuous, non-invasive monitoring without requiring specific tasks from users, making it a cost-effective alternative to traditional diagnostic methods. The platform not only diagnoses conditions but also tracks therapeutic effectiveness, enabling better communication between clinicians and patients. By focusing on early detection and reliable disease progression markers, nQ Medical aims to enhance the management of neurological disorders and prepare for the future introduction of disease-modifying therapies.

Eko Health

Series B in 2019
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Embr Labs

Series B in 2019
Embr Labs Inc. is a thermal wellness technology company based in Somerville, Massachusetts, that specializes in developing and selling wearable devices designed to adjust body temperature for enhanced comfort. Originally founded as Wristify Inc. in 2014, the company rebranded in 2015. Embr Labs leverages patented technology to utilize thermal sensations as a means to influence the autonomic nervous system, aiding individuals in managing conditions such as hot flashes, sleep disturbances, and anxiety. The company's innovative approach combines thermal stimulation with digital interventions through a mobile app and cloud infrastructure, creating a comprehensive platform for users. With tens of thousands of customers across 170 countries, Embr Labs has recorded over 100 million minutes of thermal interventions. The technology was conceived by its founders while they were engineering students at MIT, and the company has received significant backing from various investors and grants.

Neosensory

Series A in 2019
Neosensory, Inc. is a company that specializes in developing wearable devices aimed at enhancing sensory perception for individuals. Founded in 2015 and based in San Mateo, California, Neosensory offers products such as Buzz, which utilizes vision-to-touch sensory substitution technology to assist blind individuals. The company focuses on transmitting various data streams to the brain through the sense of touch, leveraging the skin's potential for information delivery. Their innovative approach includes building hearing assistive technology that allows users to perceive sound through vibrations on the skin. Neosensory also provides a companion application for its products, enhancing the user experience and accessibility of information.

Savonix

Series A in 2018
Savonix, Inc. is a company that develops an evidence-based digital neuro-cognitive assessment platform aimed at enhancing brain health. Its flagship product, Savonix Mobile, allows users to conduct clinically recognized cognitive assessments directly on their mobile devices. This platform serves a diverse clientele, including healthcare providers, researchers, and large corporations, enabling them to evaluate cognitive function in various domains such as memory and cognitive flexibility. The assessments are guided and reported by a virtual clinician, facilitating the understanding of risks associated with dementia and other brain disorders. Notably, Savonix incorporates a unique 3D game platform that derives insights into cognitive functions, such as Implicit Learning, from user interactions within the app. Founded in 2014 and based in San Francisco, Savonix has established strategic partnerships with institutions like New York University and several biotechnology firms to enhance its offerings and impact in the field of cognitive health.

LifeLink Systems

Series A in 2018
LifeLink Systems is a healthcare technology company that specializes in conversational engagement solutions. It partners with major healthcare systems and pharmaceutical companies to facilitate communication with patients through mobile and messaging platforms. By deploying and managing advanced chatbot technology, LifeLink enables personalized and contextually relevant conversations throughout the patient care continuum. This innovative approach automates numerous critical patient interactions before, during, and after healthcare visits, leading to enhanced operational efficiency and increased customer satisfaction. Through its services, LifeLink not only improves patient engagement but also fosters greater brand loyalty for healthcare providers.

Eko Health

Series A in 2018
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Tissue Analytics

Series A in 2018
Tissue Analytics, Inc. is a Baltimore-based company that specializes in developing a mobile application aimed at improving the management of chronic wounds, burns, and skin conditions. Founded in 2014, the company provides a solution for home health agencies, nursing homes, and medical practices to capture patient photographs and perform wound analysis. The platform automatically generates formatted patient reports and enables tracking of treatment progress. It also includes remote evaluation tools and employs advanced algorithms for skin and wound analysis, ensuring secure transmission of protected health information from patients to healthcare providers. Tissue Analytics operates as a subsidiary of Net Health Systems, Inc. and has formed a strategic alliance with MolecuLight Inc.

Siris Medical

Series A in 2017
Siris Medical, Inc. is a company based in Redwood City, California, that specializes in artificial intelligence-driven decision support systems for radiation therapy in cancer treatment. Founded in 2013, it has developed the InsightRT Software Suite, which includes tools such as QuickMatch and PlanMD that can function independently or in conjunction. The company has successfully commercialized the first FDA-cleared artificial intelligence decision support platform specifically for radiation oncology. This innovative platform utilizes machine learning to assist clinicians in making informed treatment decisions, optimizing variables like dose, prescription, and modality. By providing real-time insights into treatment outcomes, Siris Medical aims to enhance the quality of cancer care while minimizing treatment-related side effects and expediting the initiation of patient treatment.

Savonix

Series A in 2017
Savonix, Inc. is a company that develops an evidence-based digital neuro-cognitive assessment platform aimed at enhancing brain health. Its flagship product, Savonix Mobile, allows users to conduct clinically recognized cognitive assessments directly on their mobile devices. This platform serves a diverse clientele, including healthcare providers, researchers, and large corporations, enabling them to evaluate cognitive function in various domains such as memory and cognitive flexibility. The assessments are guided and reported by a virtual clinician, facilitating the understanding of risks associated with dementia and other brain disorders. Notably, Savonix incorporates a unique 3D game platform that derives insights into cognitive functions, such as Implicit Learning, from user interactions within the app. Founded in 2014 and based in San Francisco, Savonix has established strategic partnerships with institutions like New York University and several biotechnology firms to enhance its offerings and impact in the field of cognitive health.

Juji

Seed Round in 2017
Juji is a company focused on democratizing artificial intelligence to enhance human interaction and automation. It offers a cloud-based software platform that enables users to create customized AI chatbots without requiring technical expertise. By leveraging advanced technologies such as deep learning, natural language processing, and machine learning, Juji's platform allows business professionals to integrate chatbots into websites and mobile applications. These chatbots can perform various functions, including greeting visitors, understanding their needs, answering queries, and providing enterprise information. Additionally, the platform provides real-time audience analytics, including topic summarization of user interactions, facilitating informed decision-making for clients.

Sensoplex

Seed Round in 2017
FITNESS & WELLNESS TRACKING MODULES All our platforms offer Bluetooth Smart (Low Energy) wireless, USB charging and data connectivity, Flash memory, and a choice of processing power & of sensors. -Now: 16 bit MCU and gyroscopes, accelerometers, compass, pressure & temperature sensors. -In Q2 2014: 32 bit MCU and, in addition to the above sensors, optional ones such as heart rate, oxygen, humidity, UV, muscle strain, etc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.